Navigation Links
Genome Sequencer 20 System from Roche Applied Science

ProductsGenome Sequencer 20 System from Roche Applied Science
Company Roche Applied Science
Item Genome Sequencer 20 System
Price 
Description The Genome Sequencer 20 System revolutionizes DNA sequencing, delivering sequence data in a massively parallel fashion.

The Genome Sequencer 20 System includes:
  • Instrument and accessories
  • Reagents and consumables for library construction, amplification, and sequencing
  • Analysis software for mapping and de novo assembly


The instrument is the centerpiece of the Genome Sequencer 20 System. It contains both optics and fluidics subsystems, which are controlled by a computer subsystem. • The fluidics subsystem ensures accurate reagent dispensing. It consists of a reagents cassette (which holds the reagent containers), a sipper manifold, pumps, valves, and debubblers • The fluidics subsystem flows the sequencing reagents across the wells of the PicoTiterPlate device, and moves the spent reagents from the PicoTiterPlate device to the waste receptacle. • The light resulting from the sequencing reaction travels through the back of the wells of the PicoTiterPlate device and is captured by the CCD camera.
Info Roche Applied ScienceRoche Applied Science
Roche Diagnostics Corporation
P.O. Box 50414
9115 Hague Road
Indianapolis, IN 46250-0414 USA




Call Roche Applied Science to buy products (US and Canada only; other locations use numbers below)
USA Canada 1-866-346-8242
Customer Service: 800-262-1640
Tech Support: 800-262-4911
Fax Number: 800-428-2883
Web Site: http://www.roche-applied-science.com
NOTE: Price information is approximate list price and actual prices may vary.

Related biology products :

1. S. pombe Whole Genome ChIP-on-chip from Agilent Technologies
2. S. cerevisiae yeast Whole Genome from Agilent Technologies
3. S. cerevisiae yeast Whole Genome from Agilent Technologies
4. HP GenomeWide siRNA from QIAGEN
5. CpGenome™ Fast DNA Modification Kit from CHEMICON
6. HEEBO Human Genome Set 200 pmol from Invitrogen
7. GenomeLab GeXP Genetic Analysis System from Beckman Coulter
8. APAgene Genome Walking Kit from Bio S&T
9. GenomePlex Single Cell Whole Genome Amplification Kit from Sigma-Aldrich
10. GenomePlex Whole Genome Amplification (WGA) kit from Sigma-Aldrich
11. GenomeLab SNPstream Genotyping System from Beckman Coulter
IgG2b, k APC clone A95-1, Isotype Rat IgG2b, kappa, 0.1 mg ....
For the differentiation of mouse embryonic stem cells tooligodendrocytes....
Mouse BLC/BCA 1 - 10kDa...
Preadipocyte factor-1 [Pref-1, DLK-1], C-terminal...
Biology Products:
(Date:5/20/2015)... OXFORD, Conn. , May 20, 2015 ... "Company") announces that its wholly owned subsidiary, 3D-ID LLC, ... contractor under Team Battelle for the biometrics technology portion ... Unrestricted Suite Contract from the Department of the Army. ... facial recognition products developed for government, law enforcement and ...
(Date:5/19/2015)... -- Technology is rapidly advancing, outpacing enterprises, ability to secure ... and their management are soon to be rendered obsolete ... as those developed by the FIDO Alliance™. With the ... BYOD, COPE, IoT, and mobile payments, the interconnected online ... In response to the call for seamless, secure, ...
(Date:5/18/2015)... May 18, 2015 Fingerprint Cards (FPC) ... FPC1025, FPC1145, FPC1155 and FPC1035 from one if its module ... and including Q3 2015 and the sensors will be used ... order values for 2015 hereby amount to 740 MSEK to ... of 140 MSEK and a number of smaller orders not ...
Breaking Biology News(10 mins):NXT-ID, Inc Announces Participation as Member of Team Battelle for TIES Contract Award 2NXT-ID, Inc Announces Participation as Member of Team Battelle for TIES Contract Award 3HYPR Corp. Biometric Security Integration Kit Shields Applications and Devices Across the Internet of Things 2HYPR Corp. Biometric Security Integration Kit Shields Applications and Devices Across the Internet of Things 3Fingerprint Cards Receives Touch Fingerprint Sensor Order of SEK 230 Million and Raises Revenue Guidance for 2015 2
... athletes looking to boost performance comes in the form of ... for its popularity is twofold says Scott Forbes, a doctoral ... for nitric oxide that is known to improve blood flow, ... to working muscles and assist with metabolic waste product removal. ...
... Bethesda, MD The Association for Molecular Pathology ... to exclusively license the subject matter of a cancer-related ... written remarks were submitted to NIH in response to ... entitled, "Prospective Grant of Exclusive License: The Development of ...
... of engineering principles to understand and treat medical conditions ... damage to the brain caused by a traumatic injury. ... presented in a special issue of Journal of ... Liebert, Inc. ( http://www.liebertpub.com ) The entire issue is ...
Cached Biology News:L-arginine: Supplement tested on fit, athletic men shows no advantage 2L-arginine: Supplement tested on fit, athletic men shows no advantage 3AMP opposes exclusive licensing of NIH proteomics patent 2Bioengineering yields new approaches for diagnosing and treating traumatic brain injury 2
(Date:6/1/2015)... (PRWEB) June 01, 2015 Sistemic ... have entered into a commercial collaboration agreement and ... will combine their technologies and work together towards ... regenerative technology. RoosterBio and Sistemic will collaborate on ... to build more precise and relevant characterization panels ...
(Date:6/1/2015)... , June 1, 2015  Berg, a biopharmaceutical company ... approach, presented clinical research from its trials using its ... and preclinical data on triple negative breast cancer, at ... Society of Clinical Oncology (ASCO), May 29 – June ... BPM 31510 is one of the first cancer ...
(Date:6/1/2015)... 29, 2015 Research and Markets( ... the "2015 Strategies in the US ... their offering. This new 373-page ... comprehensive analysis of the POC clinical chemistry ... requirements, technological trends, competitive landscape, and emerging ...
(Date:6/1/2015)... June 1, 2015  Asterias Biotherapeutics, Inc. (NYSE ... emerging field of regenerative medicine, today announced positive, ... clinical trial of AST-VAC1 in patients with intermediate ... is the Company,s autologous (using cells sourced from ... is the most common form of acute leukemia ...
Breaking Biology Technology:Sistemic and RoosterBio Inc Announce Broad Collaboration Agreement to Advance miRNA and Mesenchymal Stem/Stromal Cell (MSC) Regenerative Technology 2Sistemic and RoosterBio Inc Announce Broad Collaboration Agreement to Advance miRNA and Mesenchymal Stem/Stromal Cell (MSC) Regenerative Technology 3Sistemic and RoosterBio Inc Announce Broad Collaboration Agreement to Advance miRNA and Mesenchymal Stem/Stromal Cell (MSC) Regenerative Technology 4Berg Presents Data On BPM 31510 Solid Tumor Trial At ASCO Annual Meeting That Reveals The Promise Of Metabolically Driven Therapy 2Berg Presents Data On BPM 31510 Solid Tumor Trial At ASCO Annual Meeting That Reveals The Promise Of Metabolically Driven Therapy 3Positive New, Long-Term Follow-Up Data of Asterias Biotherapeutics' AST-VAC1 Cancer Vaccine Demonstrates Prolonged Relapse-Free Survival in Patients with High-Risk Acute Myelogenous Leukemia (AML) 2Positive New, Long-Term Follow-Up Data of Asterias Biotherapeutics' AST-VAC1 Cancer Vaccine Demonstrates Prolonged Relapse-Free Survival in Patients with High-Risk Acute Myelogenous Leukemia (AML) 3Positive New, Long-Term Follow-Up Data of Asterias Biotherapeutics' AST-VAC1 Cancer Vaccine Demonstrates Prolonged Relapse-Free Survival in Patients with High-Risk Acute Myelogenous Leukemia (AML) 4Positive New, Long-Term Follow-Up Data of Asterias Biotherapeutics' AST-VAC1 Cancer Vaccine Demonstrates Prolonged Relapse-Free Survival in Patients with High-Risk Acute Myelogenous Leukemia (AML) 5Positive New, Long-Term Follow-Up Data of Asterias Biotherapeutics' AST-VAC1 Cancer Vaccine Demonstrates Prolonged Relapse-Free Survival in Patients with High-Risk Acute Myelogenous Leukemia (AML) 6Positive New, Long-Term Follow-Up Data of Asterias Biotherapeutics' AST-VAC1 Cancer Vaccine Demonstrates Prolonged Relapse-Free Survival in Patients with High-Risk Acute Myelogenous Leukemia (AML) 7